Clin2
NCT07251023Possibly a fitRecruiting

Testing a new drug for Alzheimer's dementia

Alzheimer Type Dementia

Treatments studied

Part of Brain & nervous system, Mental health clinical trials.

This study tests whether a new drug called Latrepirdine (DMB-I) is safe and effective for people with mild to moderate Alzheimer's dementia. It may help slow cognitive decline when added to current treatment or used alone.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
450 people
Ages
60 years to 90 years
Study type
Interventional

Who can take part

  • You are between 60 and 90 years old.
  • You have been diagnosed with mild to moderate Alzheimer's disease.
  • You either take memantine 20 mg daily for at least 2 months or have not taken any dementia medications for 2 months or more.
  • You have a caregiver who can be with you often and attend all study visits.
  • You have not had a stroke or significant brain injury from strokes.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07489599Not yet recruiting· Phase 1
Study of a new drug for mild Alzheimer's disease

This study tests a new drug, QLH2405, for people with mild cognitive impairment or mild Alzheimer's disease. It aims to see if the drug is safe and how it affects memory and thinking.

NCT07058688Recruiting· Phase 2
Testing a new drug for Alzheimer's (NTRX-07)

This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.

Brno
NCT07191028Not yet recruiting· Phase 3
Testing Neuroaid II for mild to moderate Alzheimer's disease

This trial tests an investigational drug called Neuroaid II (MLC901) for people with mild to moderate Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.

Singapore
NCT06535308Recruiting· Phase 1
Testing a new Alzheimer's drug for moderate disease

This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.

Seoul, Jongno-gu
NCT06885567Not yet recruiting· Phase 2
Testing BEY2153 for Early Alzheimer's Disease

This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease (mild cognitive impairment or mild dementia). The goal is to see if it is safe and slows down memory decline.

Seoul
NCT07781657Not yet recruiting· Phase 2
Testing an experimental drug for early Alzheimer's disease

This study tests an experimental medication called RO7568282 to see if it can slow down memory decline in people with early Alzheimer's disease. If you have early memory problems and a confirmed Alzheimer's-related brain change, you may be able to join.

Hear when a new Alzheimer Type Dementia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.